gen1046
mAbexperimentalMulti-specific
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started May 14, 2019 (NCT03917381)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 2
- Melanoma · Phase 2
- Neoplasms · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
TNFRSF9 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095337 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06984328 | Phase 2 | Jul 25, 2025 | Genmab |
| NCT06635824 | Phase 3 | Nov 30, 2024 | Biontech, Genmab |
| NCT06046274 | Phase 2 | Jan 15, 2024 | Biontech, Genmab |
| NCT05117242 | Phase 2 | Oct 27, 2021 | Biontech, Genmab |
| NCT04937153 | Phase 1 | Jun 15, 2021 | Biontech, Genmab |
| NCT03917381 | Phase 1/Phase 2 (Phase 2) | May 14, 2019 | Biontech, Genmab |
Showing 6 of 6 trials
Page 1 / 1